The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

uke.de

About University Medical Center Hamburg-Eppendorf

University Medical Center Hamburg-Eppendorf is a medical clinic.

University Medical Center Hamburg-Eppendorf Headquarters Location

Martinistrasse 52

Hamburg, 20246,

Germany

+49 04074100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

University Medical Center Hamburg-Eppendorf Patents

University Medical Center Hamburg-Eppendorf has filed 4 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/10/2016

12/15/2020

Clusters of differentiation, Monoclonal antibodies, Immune system, Immunology, Proteins

Grant

Application Date

11/10/2016

Grant Date

12/15/2020

Title

Related Topics

Clusters of differentiation, Monoclonal antibodies, Immune system, Immunology, Proteins

Status

Grant

Latest University Medical Center Hamburg-Eppendorf News

A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease

Jul 2, 2021

Jorma Isola, M.D., Ph.D., for the CEC-3 Trial Group * A complete list of the investigators and contributors in the CEC-3 Trial Group is provided in the Supplementary Appendix , available at NEJM.org. Drs. Schuppan and Mäki contributed equally to this article. Background In celiac disease, small intestinal transglutaminase 2 causes deamidation of glutamine residues in gluten peptides, which enhances stimulation of T cells and leads to mucosal injury. Inhibition of transglutaminase 2 is a potential treatment for celiac disease. Methods Download a PDF of the Research Summary . In a proof-of-concept trial, we assessed the efficacy and safety of a 6-week treatment with ZED1227, a selective oral transglutaminase 2 inhibitor, at three dose levels as compared with placebo, in adults with well-controlled celiac disease who underwent a daily gluten challenge. The primary end point was the attenuation of gluten-induced mucosal damage, as measured by the ratio of villus height to crypt depth. Secondary end points included intraepithelial lymphocyte density, the Celiac Symptom Index score, and the Celiac Disease Questionnaire score (for assessment of health-related quality of life). Results Of the 41 patients assigned to the 10-mg ZED1227 group, the 41 assigned to the 50-mg group, the 41 assigned to the 100-mg group, and the 40 assigned to the placebo group, 35, 39, 38, and 30 patients, respectively, had adequate duodenal-biopsy samples for the assessment of the primary end point. Treatment with ZED1227 at all three dose levels attenuated gluten-induced duodenal mucosal injury. The estimated difference from placebo in the change in the mean ratio of villus height to crypt depth from baseline to week 6 was 0.44 (95% confidence interval [CI], 0.15 to 0.73) in the 10-mg group (P=0.001), 0.49 (95% CI, 0.20 to 0.77) in the 50-mg group (P<0.001), and 0.48 (95% CI, 0.20 to 0.77) in the 100-mg group (P<0.001). The estimated differences from placebo in the change in intraepithelial lymphocyte density were −2.7 cells per 100 epithelial cells (95% CI, −7.6 to 2.2) in the 10-mg group, −4.2 cells per 100 epithelial cells (95% CI, −8.9 to 0.6) in the 50-mg group, and −9.6 cells per 100 epithelial cells (95% CI, −14.4 to −4.8) in the 100-mg group. Use of the 100-mg dose may have improved symptom and quality-of-life scores. The most common adverse events, the incidences of which were similar across all groups, were headache, nausea, diarrhea, vomiting, and abdominal pain. Rash developed in 3 of 40 patients (8%) in the 100-mg group. Conclusions In this preliminary trial, treatment with ZED1227 attenuated gluten-induced duodenal mucosal damage in patients with celiac disease. (Funded by Dr. Falk Pharma; CEC-3 EudraCT number, 2017-002241-30 .) . Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. Drs. Schuppan and Mäki contributed equally to this article. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org. We thank the patients and their families and the trial teams at the participating trial centers; Martin Krauss (statistician), Gerd Bouma (gastroenterologist), and Gino Corazza (gastroenterologist) for serving as members of the independent data monitoring committee; Anneli Vuorinen and Johanna Haikonen (both from Crown CRO) for assistance in conducting the clinical trial; Anni Rava, Kaisa Laapas, and Inger-Helen Maadik (all from StatFinn, an IQVIA company) for data management and statistical expertise; Tiina Kärjä-Lahdensuu (from CO Consult) for local operational and regulatory assistance; Sibylle Neufang (University Medical Center, Mainz, Germany) for local operational assistance; the staff of the Finnish Celiac Society (Keliakialiitto), the German Celiac Society (Deutsche Zöliakiegesellschaft), and the Swiss Celiac Association (IG Zöliakie der Deutschen Schweiz) for generosity and assistance; and Jun Yan (of Jun Yan Medical Writings) for writing the first draft of the manuscript and for providing native-speaker linguistic and grammatical review of earlier versions of the manuscript. Author Affiliations From the Institute of Translational Immunology and Celiac Center, Research Center for Immune Therapy, University Medical Center, Johannes Gutenberg University, Mainz (D.S., T.F.-S.), the Department of Internal and Integrative Medicine, Sozialstiftung Bamberg, Bamberg (J.L. ), the Department of Integrative Medicine, University of Duisburg-Essen, Duisburg-Essen (J.L. ), the Division of Gastroenterology, Hepatology, and Infectious Diseases, Department of Internal Medicine I, University Hospital Tübingen, Tübingen (S.F. ), the Department of Gastroenterology, Infectious Diseases, and Rheumatology, Campus Benjamin Franklin, Charité–University Medicine Berlin, Berlin (M. Schumann), the Department of Medicine II, University Hospital, Ludwig Maximilians University, Munich (H.P.T. ), the Department of Medicine 1, Hector Center for Nutrition, Exercise, and Sports, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen (Y.Z. ), the Department of Medicine I, University Medical Center Hamburg-Eppendorf, Hamburg (A.W.L. ), the Department of Internal Medicine IV, University Hospital, Friedrich-Schiller University Jena, Jena (A.S.), and Dr. Falk Pharma, Freiburg (R.M., R.G.) — all in Germany; the Division of Gastroenterology and Celiac Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (D.S. ); the Faculty of Medicine and Health Technology, Tampere University and Tampere University Hospital (M.M., A.P., M.-L.L. ), the Faculty of Medicine and Health Technology, Tampere University (J.I., J.T. ), Jilab (J.I. ), and the Department of Pediatrics, Tampere University Hospital (M.-L.L. ), Tampere, the Department of Internal Medicine, Central Finland Central Hospital, Jyväskylä (J.T. ), Lääkärikeskus Aava Helsinki Kamppi, Helsinki (J. Koskenpato), and Clinical Research Services Turku, Turku (M. Scheinin) — all in Finland; Oslo University Hospital, Rikshospitalet, and Stiftelsen K.G. Jebsen Celiac Disease Research Center, University of Oslo, Oslo (K.E.A.L. ), the Medical Department, Innlandet Hospital Trust, Gjøvik (O.H. ), and Akershus University Hospital, Lørenskog (J.J.) — all in Norway; the University of Medicine and Pharmacy “Carol Davila” and the National Institute for Mother and Child Health “Alessandrescu-Rusescu,” Bucharest, Romania (A.P. ); the Gastroenterology Department and Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania (J. Kupcinskas); the Department of Gastroenterology, Internal Medicine Clinic, Tartu University Hospital, Tartu, Estonia (K.K. ); the Department of Gastroenterology and Hepatology, University Hospital Zurich (L.B., J.Z. ), and the Swiss Celiac Center, Center of Gastroenterology, Clinic Hirslanden (J.Z.) — both in Zurich, Switzerland; and University College Hospital Galway, Galway, Ireland (V.B.). Address reprint requests to Dr. Schuppan at the Institute of Translational Immunology and Celiac Center, Research Center for Immune Therapy, University Medical Center, Johannes Gutenberg University, Langenbeckstr. 1, 55131 Mainz, Germany, or at [email protected] . A complete list of the investigators and contributors in the CEC-3 Trial Group is provided in the Supplementary Appendix , available at NEJM.org. Share

University Medical Center Hamburg-Eppendorf Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

University Medical Center Hamburg-Eppendorf Rank

  • Where is University Medical Center Hamburg-Eppendorf's headquarters?

    University Medical Center Hamburg-Eppendorf's headquarters is located at Martinistrasse 52, Hamburg.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.